scancell.co.uk
Open in
urlscan Pro
2606:4700:20::681a:d78
Public Scan
Submitted URL: http://scancell.co.uk/
Effective URL: https://scancell.co.uk/
Submission: On January 01 via api from US — Scanned from DE
Effective URL: https://scancell.co.uk/
Submission: On January 01 via api from US — Scanned from DE
Form analysis 2 forms found in the DOM
POST https://scancell.co.uk/
<form method="post" action="https://scancell.co.uk/" id="aspnetForm" class="main-form">
<div class="aspNetHidden">
<input type="hidden" name="__EVENTTARGET" id="__EVENTTARGET" value="">
<input type="hidden" name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="">
<input type="hidden" name="__VIEWSTATEFIELDCOUNT" id="__VIEWSTATEFIELDCOUNT" value="12">
<input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE"
value="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">
<input type="hidden" name="__VIEWSTATE1" id="__VIEWSTATE1"
value="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">
<input type="hidden" name="__VIEWSTATE2" id="__VIEWSTATE2"
value="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">
<input type="hidden" name="__VIEWSTATE3" id="__VIEWSTATE3"
value="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">
<input type="hidden" name="__VIEWSTATE4" id="__VIEWSTATE4"
value="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">
<input type="hidden" name="__VIEWSTATE5" id="__VIEWSTATE5"
value="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">
<input type="hidden" name="__VIEWSTATE6" id="__VIEWSTATE6"
value="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">
<input type="hidden" name="__VIEWSTATE7" id="__VIEWSTATE7"
value="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">
<input type="hidden" name="__VIEWSTATE8" id="__VIEWSTATE8"
value="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">
<input type="hidden" name="__VIEWSTATE9" id="__VIEWSTATE9"
value="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">
<input type="hidden" name="__VIEWSTATE10" id="__VIEWSTATE10"
value="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">
<input type="hidden" name="__VIEWSTATE11" id="__VIEWSTATE11"
value="eJ2KOAU37kSl7vy7l502IcMOGpDgM8seSoNgSzq+mRXw2yCHxgoOP07JFy6CjFKUh4b+d2ANwfsprl/WnboKPKDHl5Z+l/ItxD9nX92kfVBmv2pf82b69nt+IXRP4Et8Rl+LUwLyeHWjoAOhnxJ5R/6W6CqaQ8nBpcShy0Fnb6OQCyiMEtJWXlMxIPXrGAmdM1hySZM/VbeXR/d/epYeq+dZnypZdI0fAyH2J9WLz83oE/CIMX/B">
</div>
<script type="text/javascript">
//<![CDATA[
var theForm = document.forms['aspnetForm'];
if (!theForm) {
theForm = document.aspnetForm;
}
function __doPostBack(eventTarget, eventArgument) {
if (!theForm.onsubmit || (theForm.onsubmit() != false)) {
theForm.__EVENTTARGET.value = eventTarget;
theForm.__EVENTARGUMENT.value = eventArgument;
theForm.submit();
}
}
//]]>
</script>
<script type="text/javascript">
//<![CDATA[
var __cultureInfo = {
"name": "en-GB",
"numberFormat": {
"CurrencyDecimalDigits": 2,
"CurrencyDecimalSeparator": ".",
"IsReadOnly": false,
"CurrencyGroupSizes": [3],
"NumberGroupSizes": [3],
"PercentGroupSizes": [3],
"CurrencyGroupSeparator": ",",
"CurrencySymbol": "£",
"NaNSymbol": "NaN",
"CurrencyNegativePattern": 1,
"NumberNegativePattern": 1,
"PercentPositivePattern": 1,
"PercentNegativePattern": 1,
"NegativeInfinitySymbol": "-Infinity",
"NegativeSign": "-",
"NumberDecimalDigits": 2,
"NumberDecimalSeparator": ".",
"NumberGroupSeparator": ",",
"CurrencyPositivePattern": 0,
"PositiveInfinitySymbol": "Infinity",
"PositiveSign": "+",
"PercentDecimalDigits": 2,
"PercentDecimalSeparator": ".",
"PercentGroupSeparator": ",",
"PercentSymbol": "%",
"PerMilleSymbol": "‰",
"NativeDigits": ["0", "1", "2", "3", "4", "5", "6", "7", "8", "9"],
"DigitSubstitution": 1
},
"dateTimeFormat": {
"AMDesignator": "AM",
"Calendar": {
"MinSupportedDateTime": "\/Date(-62135596800000)\/",
"MaxSupportedDateTime": "\/Date(253402300799999)\/",
"AlgorithmType": 1,
"CalendarType": 1,
"Eras": [1],
"TwoDigitYearMax": 2029,
"IsReadOnly": false
},
"DateSeparator": "/",
"FirstDayOfWeek": 1,
"CalendarWeekRule": 2,
"FullDateTimePattern": "dd MMMM yyyy HH:mm:ss",
"LongDatePattern": "dd MMMM yyyy",
"LongTimePattern": "HH:mm:ss",
"MonthDayPattern": "d MMMM",
"PMDesignator": "PM",
"RFC1123Pattern": "ddd, dd MMM yyyy HH\u0027:\u0027mm\u0027:\u0027ss \u0027GMT\u0027",
"ShortDatePattern": "dd/MM/yyyy",
"ShortTimePattern": "HH:mm",
"SortableDateTimePattern": "yyyy\u0027-\u0027MM\u0027-\u0027dd\u0027T\u0027HH\u0027:\u0027mm\u0027:\u0027ss",
"TimeSeparator": ":",
"UniversalSortableDateTimePattern": "yyyy\u0027-\u0027MM\u0027-\u0027dd HH\u0027:\u0027mm\u0027:\u0027ss\u0027Z\u0027",
"YearMonthPattern": "MMMM yyyy",
"AbbreviatedDayNames": ["Sun", "Mon", "Tue", "Wed", "Thu", "Fri", "Sat"],
"ShortestDayNames": ["Su", "Mo", "Tu", "We", "Th", "Fr", "Sa"],
"DayNames": ["Sunday", "Monday", "Tuesday", "Wednesday", "Thursday", "Friday", "Saturday"],
"AbbreviatedMonthNames": ["Jan", "Feb", "Mar", "Apr", "May", "Jun", "Jul", "Aug", "Sep", "Oct", "Nov", "Dec", ""],
"MonthNames": ["January", "February", "March", "April", "May", "June", "July", "August", "September", "October", "November", "December", ""],
"IsReadOnly": false,
"NativeCalendarName": "Gregorian Calendar",
"AbbreviatedMonthGenitiveNames": ["Jan", "Feb", "Mar", "Apr", "May", "Jun", "Jul", "Aug", "Sep", "Oct", "Nov", "Dec", ""],
"MonthGenitiveNames": ["January", "February", "March", "April", "May", "June", "July", "August", "September", "October", "November", "December", ""]
},
"eras": [1, "A.D.", null, 0]
}; //]]>
</script>
<script src="/ScriptResource.axd?d=_jk4V8Fd8MesKyOkWRxj3sZ08acCOO_fz1INM7LY_B0U3Lmy1Hi2wH3xqcnI1uF8Uh99yReWF-uegwePFUqDTHyGXNHB6Rg758DfDI7tmS2wEXFKIFVFfkXmNW0iN1k_ZFA2eQ2" type="text/javascript"></script>
<script src="//ajax.aspnetcdn.com/ajax/4.5/6/WebFormsBundle.js" type="text/javascript"></script>
<script src="//ajax.aspnetcdn.com/ajax/4.5/6/MsAjaxBundle.js" type="text/javascript"></script>
<script type="text/javascript">
//<![CDATA[
if (typeof(Sys) === 'undefined') throw new Error('ASP.NET Ajax client-side framework failed to load.');
//]]>
</script>
<div class="aspNetHidden">
<input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="CA0B0334">
<input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="fTwuN2LennJB+Bw0OHYnjNIsl8fCEAdUyK9sqeLeedp78n6Q8Ven2O/xDhZU1S8kn+kp5tu6LeXpUd6Ixxf+vj8jX/w6JC1MHygAqP8nrREFwABX">
</div>
<script type="text/javascript">
//<![CDATA[
Sys.WebForms.PageRequestManager._initialize('ctl00$ScriptManager1', 'aspnetForm', [], [], [], 90, 'ctl00');
//]]>
</script>
<!--[if lt IE 9]>
<div class="alert alert-warning alert-dismissible alert-browser" role="alert">
<div class="container">
<button type="button" class="close" data-dismiss="alert" aria-label="Close"><span aria-hidden="true">×</span></button>
<strong><span class="fa fa-exclamation-triangle fa-fw"></span> Attention!</strong> Your browser is <strong>out-dated.</strong> Please upgrade to a different browser. Go to <a class="alert-link" href="http://browsehappy.com/" target="_blank" title="Online. Worry-free. Upgrade your browser today!">BrowseHappy.com</a> to learn about better and safer browsing.<br>
<strong><span class="fa fa-info-circle fa-fw"></span> NOTE:</strong> If you are seeing this message in IE 9-11 please turn off IE Compatibility View to experience this site to the fullest extent!
</div>
</div>
<![endif]-->
<script>
var hideAdminDrawerInitially = true;
var autoHideAdminDrawer = true;
</script>
<!-- No page warning -->
<div class="sitewrap">
<header class="sc-head" role="banner">
<nav class="navbar navbar-default navbar-static-top navbar-site">
<div class="row">
<div class="col-xs-4 col-sm-6 col-md-6 col-lg-3">
<a href="/" title="Scancell" class="navbar-brand navbar-logo"><img class="site-logo" alt="Scancell" src="/Data/Sites/1/media/logos/scancell-logo.png"></a>
</div>
<div class="hidden-lg col-xs-8 col-sm-6 col-md-6">
<div class="wrapsearchbtn">
<a href="\SearchResults.aspx" title="Search the web site" class="btn btn-search">
<div class="fa fa-search sc-srchicon"></div><div class="sc-srchtext">SEARCH</div>
</a>
</div>
<div class="navbar-header fb-parent fb-row fb-ai-center fb-j-start">
<button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#site-menu" aria-expanded="false">
<span class="sr-only">Toggle navigation</span>
<!-- <span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="icon-bar"></span> -->
<span class="fa fa-bars"></span>
</button>
</div>
</div>
<div class="col-xs-12 col-sm-12 col-md-12 col-lg-9">
<div class="collapse navbar-collapse" id="site-menu">
<ul class="sc-sitenav nav navbar-nav navbar-right" data-smartmenus-id="16725805589829514">
<li class="active"><a href="/home">HOME</a></li>
<li class="dropdown-toggle"><a href="/company" class="has-submenu" id="sm-16725805589829514-1" aria-haspopup="true" aria-controls="sm-16725805589829514-2" aria-expanded="false">COMPANY <span class="caret"></span></a>
<ul class="dropdown-menu" id="sm-16725805589829514-2" role="group" aria-hidden="true" aria-labelledby="sm-16725805589829514-1" aria-expanded="false">
<li><a href="/board-of-directors">BOARD OF DIRECTORS</a></li>
<li><a href="/management">MANAGEMENT</a></li>
<li><a href="/partnerships">PARTNERSHIPS</a></li>
<li><a href="/careers">CAREERS</a></li>
</ul>
</li>
<li class="dropdown-toggle"><a href="/vaccines" class="has-submenu" id="sm-16725805589829514-3" aria-haspopup="true" aria-controls="sm-16725805589829514-4" aria-expanded="false">VACCINES <span class="caret"></span></a>
<ul class="dropdown-menu" id="sm-16725805589829514-4" role="group" aria-hidden="true" aria-labelledby="sm-16725805589829514-3" aria-expanded="false">
<li class="dropdown-toggle"><a href="/moditope" class="has-submenu" id="sm-16725805589829514-5" aria-haspopup="true" aria-controls="sm-16725805589829514-6" aria-expanded="false">MODITOPE <span class="caret"></span></a>
<ul class="dropdown-menu" id="sm-16725805589829514-6" role="group" aria-hidden="true" aria-labelledby="sm-16725805589829514-5" aria-expanded="false">
<li><a href="/modi-1">Modi-1</a></li>
<li><a href="/modi-2">Modi-2</a></li>
</ul>
</li>
<li class="dropdown-toggle"><a href="/immunobody" class="has-submenu" id="sm-16725805589829514-7" aria-haspopup="true" aria-controls="sm-16725805589829514-8" aria-expanded="false">IMMUNOBODY <span class="caret"></span></a>
<ul class="dropdown-menu" id="sm-16725805589829514-8" role="group" aria-hidden="true" aria-labelledby="sm-16725805589829514-7" aria-expanded="false">
<li><a href="/scib1-iscib1">SCIB1 & iSCIB1+</a></li>
<li><a href="/scib2-iscib2">SCIB2 & iSCIB2</a></li>
<li><a href="/covidity">COVIDITY</a></li>
</ul>
</li>
<li><a href="/vaccine-publications">VACCINE PUBLICATIONS</a></li>
</ul>
</li>
<li class="dropdown-toggle"><a href="/antibodies" class="has-submenu" id="sm-16725805589829514-9" aria-haspopup="true" aria-controls="sm-16725805589829514-10" aria-expanded="false">ANTIBODIES <span class="caret"></span></a>
<ul class="dropdown-menu" id="sm-16725805589829514-10" role="group" aria-hidden="true" aria-labelledby="sm-16725805589829514-9" aria-expanded="false">
<li class="dropdown-toggle"><a href="/glymab" class="has-submenu" id="sm-16725805589829514-11" aria-haspopup="true" aria-controls="sm-16725805589829514-12" aria-expanded="false">GLYMAB <span class="caret"></span></a>
<ul class="dropdown-menu" id="sm-16725805589829514-12" role="group" aria-hidden="true" aria-labelledby="sm-16725805589829514-11" aria-expanded="false">
<li><a href="/anti-glycan-mab">ANTI-GLYCAN MAB</a></li>
</ul>
</li>
<li><a href="/avidimab">AVIDIMAB</a></li>
<li><a href="/antibody-publications">ANTIBODY PUBLICATIONS</a></li>
</ul>
</li>
<li class="dropdown-toggle"><a href="/investors" class="has-submenu" id="sm-16725805589829514-13" aria-haspopup="true" aria-controls="sm-16725805589829514-14" aria-expanded="false">INVESTORS <span class="caret"></span></a>
<ul class="dropdown-menu" id="sm-16725805589829514-14" role="group" aria-hidden="true" aria-labelledby="sm-16725805589829514-13" aria-expanded="false">
<li><a href="/company-profile">COMPANY PROFILE</a></li>
<li><a href="/advisors">ADVISORS</a></li>
<li><a href="/corporate-governance">CORPORATE GOVERNANCE</a></li>
<li><a href="/documents-presentations">DOCUMENTS & PRESENTATIONS</a></li>
<li><a href="/share-info">SHARE INFO</a></li>
<li><a href="/financial-info">FINANCIAL INFO</a></li>
<li><a href="/2020-capital-raise">2020 CAPITAL RAISE</a></li>
<li><a href="/regulatory-news">REGULATORY NEWS</a></li>
<li><a href="/regulatory-news-archive">REGULATORY NEWS ARCHIVE</a></li>
</ul>
</li>
<li class="dropdown-toggle"><a href="/news" class="has-submenu" id="sm-16725805589829514-15" aria-haspopup="true" aria-controls="sm-16725805589829514-16" aria-expanded="false">NEWS <span class="caret"></span></a>
<ul class="dropdown-menu" id="sm-16725805589829514-16" role="group" aria-hidden="true" aria-labelledby="sm-16725805589829514-15" aria-expanded="false">
<li><a href="/latest-news">LATEST NEWS</a></li>
<li><a href="/interviews">INTERVIEWS</a></li>
<li><a href="/media-coverage">MEDIA COVERAGE</a></li>
<li><a href="/webcasts">WEBCASTS</a></li>
<li><a href="/year-2022">YEAR - 2022</a></li>
<li><a href="/year-2021">YEAR - 2021</a></li>
<li><a href="/year-2020">YEAR - 2020</a></li>
<li><a href="/year-2019">YEAR - 2019</a></li>
<li><a href="/year-2018">YEAR - 2018</a></li>
<li><a href="/year-2017">YEAR - 2017</a></li>
<li><a href="/year-2016">YEAR - 2016</a></li>
<li><a href="/year-2015">YEAR - 2015</a></li>
</ul>
</li>
<li><a href="/contact-us">CONTACT US</a></li>
</ul>
</div>
<div class="wrapsearchbtn visible-lg">
<a href="\SearchResults.aspx" title="Search the web site" class="btn btn-search">
<div class="fa fa-search sc-srchicon"></div><div class="sc-srchtext">SEARCH</div>
</a>
</div>
</div>
</div>
</nav>
</header>
<main class="main-content">
<div class=" cmszone top-pane clearfix">
<div class="outerwrap SCHmPgBanner-module">
<div class="panelwrapper flexi">
<div class="outerbody">
<div class="modulecontent">
<div id="module81" data-contentsection="Harnessing Immunology to Fight Disease" class="SCHmPgBanner">
<div class="SCHmPgBanner__items">
<div class="SCHmPgBanner__group row fb-parent fb-row fb-wrap">
<div class="SCHmPgBanner__item col-sm-6 fb-shrink fb-grow fb-j-between fb-sm-100 fb-lg-50">
<div class="sc-heroimg-container">
<img class="sc-heroimg" src="/Data/Sites/1/media/img/scan_home_banner_03.jpg" alt="Harnessing Immunology to Fight Disease">
<div class="sc-heroimg-text">
<h1>Harnessing Immunology to Fight Disease</h1>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="container-fluid">
<div class="row" id="start-content">
<div id="ctl00_divCenter" class="col-md-12 nomargins center-pane clearfix">
<div class="outerwrap">
<div class="panelwrapper htmlmodule">
<a id="module34" class="moduleanchor"></a>
<div class="outerbody">
<div class="modulecontent">
<div id="ctl00_mainContent_ctl00_divContent">
<p>Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant
unmet needs in cancer and infectious disease. Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells,
Scancell uses either <strong><span class="SC-vaccine_fg">vaccines</span></strong> to induce immune responses or monoclonal <strong><span class="SC-antibody_fg">antibodies</span></strong> to redirect immune cells or drugs.</p>
<p>The company’s innovative products target post-translational modifications of proteins and lipids. For the vaccines this includes citrullination and homocitrullination of proteins, whereas the monoclonal antibodies target the
glycans or sugars on proteins and/or lipids.</p>
</div>
<input type="hidden" name="ctl00$mainContent$ctl00$hdnIsDirty" id="ctl00_mainContent_ctl00_hdnIsDirty">
</div>
</div>
</div>
</div>
<div class="outerwrap">
<div class="panelwrapper htmlfraginclude">
<a id="module162" class="moduleanchor"></a>
<div class="outerbody">
<div class="modulecontent">
<div class="SC-vablock">
<div class="row">
<div class="col-md-6">
<div class="SC-vacpanel">
<a href="/vaccines"><img alt="Vaccines" src="/Data/Sites/1/media/img/vaccines-hdr.png">
</a>
</div>
<h2><a href="/moditope"><img alt="Moditope" src="/Data/Sites/1/media/img/moditope-hdr-sm.png"> </a></h2>
<p>A driver in the vaccine portfolio is Moditope®, a completely novel class of cancer vaccines that induce potent CD4 cytotoxic T cells that seek out and destroy cancer cells by targeting citrullinated or homocitrullinated
proteins.</p>
<h2><a href="/immunobody"><img alt="Immunobody" src="/Data/Sites/1/media/img/immunobody-hdr-sm.png"> </a></h2>
<p>ImmunoBody® vaccines are designed to induce potent cytotoxic CD8 T cell responses against multiple epitopes via a dual mechanism of action. These DNA vaccines are being used both for the treatment of cancer as well as the
development of a next-generation, potentially pan-coronavirus, vaccine against SARS-CoV-2, the virus that causes COVID-19.</p>
<p><img alt="VaccinesTimeLine" class="image-left" src="/Data/Sites/1/media/img/TmLn_V_1.png"></p>
<p><a href="/moditope" title="View Moditope information"><img alt="Moditope" class="image-left" src="/Data/Sites/1/media/img/TmLn_V_2.png"></a></p>
<p><a href="/modi-1" title="View Modi-1 information"><img alt="modi_1" class="image-left" src="/Data/Sites/1/media/img/TmLn_V_3.png"></a></p>
<p><a href="/modi-2" title="View Modi-2 information"><img alt="modi_2" class="image-left" src="/Data/Sites/1/media/img/TmLn_V_4.png"></a></p>
<p><a href="/immunobody" title="View Immunobody information"><img alt="immunobody" class="image-left" src="/Data/Sites/1/media/img/TmLn_V_5.png"></a></p>
<p><a href="/scib1" title="View SCIB1 information"><img alt="SCIB1" class="image-left" src="/Data/Sites/1/media/img/TmLn_V_6.png"></a></p>
<p><a href="/covidity" title="View Covidity information"><img alt="covidity" class="image-left" src="/Data/Sites/1/media/img/TmLn_V_7.png"></a></p>
<p><a href="/scib2-iscib2" title="View iSCIB1 information"><img alt="iSCIB1" class="image-left" src="/Data/Sites/1/media/img/TmLn_V_8.png"></a></p>
</div>
<div class="col-md-6">
<div class="SC-abpanel">
<a href="/antibodies"><img alt="Antibodies" src="/Data/Sites/1/media/img/antibodies-hdr.png">
</a>
</div>
<h2><a href="/glymab"><img alt="Glymab" src="/Data/Sites/1/media/img/GlyMab-hdr-v2-sm.png"> </a></h2>
<p>The GlyMab® platform is being used to discover and develop a portfolio of innovative anti-cancer monoclonal antibodies (mAbs) that target sugar motifs (glycans) present on lipids and/or proteins. These GlyMab® mAbs have
ultra-high specificity and are expected to have utility in a wide range of cancers.</p>
<h2><a href="/avidimab"><img alt="AvidiMab" src="/Data/Sites/1/media/img/avidimab-hdr-sm.png"> </a></h2>
<p>The AvidiMab® platform is a highly versatile approach that has been designed to enhance the potency and efficacy of any clinical antibody or antibody-based product (including those based on the ImmunoBody®
platform).<br> <br></p>
<p><img alt="AntibodiesTimeLine" class="image-left" src="/Data/Sites/1/media/img/TmLn_A_v3_1.png"></p>
<p><a href="/glymab" title="View GlyMab information"><img alt="GlyMab" class="image-left" src="/Data/Sites/1/media/img/TmLn_A_v3_2.png"></a></p>
<p><a href="/anti-glycan-mab" title="View Anti-Glycan mAb portfolio"><img alt="Anti-Glycan" class="image-left" src="/Data/Sites/1/media/img/TmLn_A_v3_3.png"></a></p>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="outerwrap">
<div class="panelwrapper blog-postlist">
<h2 id="module35" class="page-header moduletitle">Latest News</h2>
<div class="outerbody">
<div class="modulecontent">
<span id="ctl00_mainContent_ctl02_postList">
<div class="blog-postlist row fb-parent fb-row fb-ai-stretch fb-ac-stretch fb-wrap">
<div class="col-sm-4 fb-child fb-grow fb-shrink fb-parent fb-row fb-wrap fb-ai-stretch fb-ac-stretch">
<article class="blog-postlist__item fb-child fb-grow fb-shrink m-b-gutter-half">
<header>
<h3 class="blog-postlist__title">
<a class="blog-postlist__item-link" href="/result-of-annual-general-meeting">Result of Annual General Meeting</a>
</h3>
</header>
<div class="blog-postlist__item-body">
<p>To download <a href="/Data/Sites/1/media/publications/rns/scancell-result-of-agm-21.11.22.pdf" target="_blank">click here</a></p>
</div>
<footer>
<div class="blog-postlist__metadata">
<span class="blog-postlist__date"><i class="fa fa-clock-o"></i> November 23, 2022</span>
</div>
</footer>
</article>
</div>
<div class="col-sm-4 fb-child fb-grow fb-shrink fb-parent fb-row fb-wrap fb-ai-stretch fb-ac-stretch">
<article class="blog-postlist__item fb-child fb-grow fb-shrink m-b-gutter-half">
<header>
<h3 class="blog-postlist__title">
<a class="blog-postlist__item-link" href="/scancell-in-licenses-vaccitech-technology-to-advance-modi-2-towards-the-clinic">Scancell in-licenses Vaccitech technology to advance Modi-2 towards the clinic</a>
</h3>
</header>
<div class="blog-postlist__item-body">
<p>To download <a href="/Data/Sites/1/media/publications/rns/scancell-in-licenses-vaccitech-technology-to-advance-modi-2-towards-the-clinic-final-07.11.22.pdf" target="_blank">click here</a></p>
</div>
<footer>
<div class="blog-postlist__metadata">
<span class="blog-postlist__date"><i class="fa fa-clock-o"></i> November 07, 2022</span>
</div>
</footer>
</article>
</div>
<div class="col-sm-4 fb-child fb-grow fb-shrink fb-parent fb-row fb-wrap fb-ai-stretch fb-ac-stretch">
<article class="blog-postlist__item fb-child fb-grow fb-shrink m-b-gutter-half">
<header>
<h3 class="blog-postlist__title">
<a class="blog-postlist__item-link" href="/first-patient-dosed-in-the-expansion-phase-of-the-monotherapy-arms-of-modify">First patient dosed in the expansion phase of the monotherapy arms of ModiFY</a>
</h3>
</header>
<div class="blog-postlist__item-body">
<p>To download <a href="/Data/Sites/1/media/publications/rns/scancell-first-patient-dosed-in-the-expansion-phase-of-the-monotherapy-arms-of-modify-final-31.10.22.pdf" target="_blank">click here</a></p>
</div>
<footer>
<div class="blog-postlist__metadata">
<span class="blog-postlist__date"><i class="fa fa-clock-o"></i> October 31, 2022</span>
</div>
</footer>
</article>
</div>
<div class="col-sm-12 blog-postlist__foot">
<p><a href="/news">View all posts</a> »</p>
</div>
</div>
</span>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</main>
</div>
<script type="text/javascript">
Sys.Application.add_load(function() {
var form = Sys.WebForms.PageRequestManager.getInstance()._form;
form._initialAction = form.action = window.location.href;
});
</script>
<script type="text/javascript">
//<![CDATA[
var callBackFrameUrl = '/WebResource.axd?d=beToSAE3vdsL1QUQUxjWddtv0UtDvCGfuXWsoSihIIPrZCMh5P54Ah139LVkpbNpe42Fmg2&t=637814653746327080';
WebForm_InitCallback(); //]]>
</script>
<script type="text/javascript">
$('div.mojo-accordion').accordion({});
$('div.mojo-accordion-nh').accordion({
heightStyle: 'content',
animate: {
opacity: 'toggle',
duration: '400'
}
});
$('div.mojo-tabs').tabs({});
$('input.jqbutton').button();
$('.jqtt').tooltip();
$('.faqs dd').hide();
$('.faqs dt').hover(function() {
$(this).addClass('hover')
}, function() {
$(this).removeClass('hover')
}).click(function() {
$(this).next().slideToggle('normal');
});
$("a.unclickable").click(function() {
return false;
});
</script>
</form>Name: mc-embedded-subscribe-form — POST https://scancell.us3.list-manage.com/subscribe/post?u=7be71e2d171ec1511abacd2ec&id=7c8f484fff
<form action="https://scancell.us3.list-manage.com/subscribe/post?u=7be71e2d171ec1511abacd2ec&id=7c8f484fff" method="post" id="mc-embedded-subscribe-form" name="mc-embedded-subscribe-form" class="validate" target="_blank" novalidate="">
<div id="mc_embed_signup_scroll">
<h2>News updates</h2>
<p>Sign up for news updates to stay up to date with Scancell</p>
<label for="mce-EMAIL">Email</label>
<input type="email" value="" name="EMAIL" class="form-control" id="mce-EMAIL" placeholder="email address" required="">
<!-- real people should not fill this in and expect good things - do not remove this or risk form bot signups-->
<div style="position: absolute; left: -5000px;" aria-hidden="true"><input type="text" name="b_7be71e2d171ec1511abacd2ec_7c8f484fff" tabindex="-1" value=""></div>
<div class="clear"><input type="submit" value="SIGN UP" name="subscribe" id="mc-embedded-subscribe" class="btn btn-default"></div>
</div>
</form>Text Content
We use cookies to ensure you get the best experience from our website.
Continue browsing and we will assume this is OK or click here to find out more.
CLOSE
SEARCH
Toggle navigation
* HOME
* COMPANY
* BOARD OF DIRECTORS
* MANAGEMENT
* PARTNERSHIPS
* CAREERS
* VACCINES
* MODITOPE
* Modi-1
* Modi-2
* IMMUNOBODY
* SCIB1 & iSCIB1+
* SCIB2 & iSCIB2
* COVIDITY
* VACCINE PUBLICATIONS
* ANTIBODIES
* GLYMAB
* ANTI-GLYCAN MAB
* AVIDIMAB
* ANTIBODY PUBLICATIONS
* INVESTORS
* COMPANY PROFILE
* ADVISORS
* CORPORATE GOVERNANCE
* DOCUMENTS & PRESENTATIONS
* SHARE INFO
* FINANCIAL INFO
* 2020 CAPITAL RAISE
* REGULATORY NEWS
* REGULATORY NEWS ARCHIVE
* NEWS
* LATEST NEWS
* INTERVIEWS
* MEDIA COVERAGE
* WEBCASTS
* YEAR - 2022
* YEAR - 2021
* YEAR - 2020
* YEAR - 2019
* YEAR - 2018
* YEAR - 2017
* YEAR - 2016
* YEAR - 2015
* CONTACT US
SEARCH
HARNESSING IMMUNOLOGY TO FIGHT DISEASE
Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate truly novel medicines to treat significant unmet
needs in cancer and infectious disease. Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise damaged or
infected cells. In order to destroy such cancerous or infected cells, Scancell
uses either vaccines to induce immune responses or monoclonal antibodies to
redirect immune cells or drugs.
The company’s innovative products target post-translational modifications of
proteins and lipids. For the vaccines this includes citrullination and
homocitrullination of proteins, whereas the monoclonal antibodies target the
glycans or sugars on proteins and/or lipids.
A driver in the vaccine portfolio is Moditope®, a completely novel class of
cancer vaccines that induce potent CD4 cytotoxic T cells that seek out and
destroy cancer cells by targeting citrullinated or homocitrullinated proteins.
ImmunoBody® vaccines are designed to induce potent cytotoxic CD8 T cell
responses against multiple epitopes via a dual mechanism of action. These DNA
vaccines are being used both for the treatment of cancer as well as the
development of a next-generation, potentially pan-coronavirus, vaccine against
SARS-CoV-2, the virus that causes COVID-19.
The GlyMab® platform is being used to discover and develop a portfolio of
innovative anti-cancer monoclonal antibodies (mAbs) that target sugar motifs
(glycans) present on lipids and/or proteins. These GlyMab® mAbs have ultra-high
specificity and are expected to have utility in a wide range of cancers.
The AvidiMab® platform is a highly versatile approach that has been designed to
enhance the potency and efficacy of any clinical antibody or antibody-based
product (including those based on the ImmunoBody® platform).
LATEST NEWS
RESULT OF ANNUAL GENERAL MEETING
To download click here
November 23, 2022
SCANCELL IN-LICENSES VACCITECH TECHNOLOGY TO ADVANCE MODI-2 TOWARDS THE CLINIC
To download click here
November 07, 2022
FIRST PATIENT DOSED IN THE EXPANSION PHASE OF THE MONOTHERAPY ARMS OF MODIFY
To download click here
October 31, 2022
View all posts »
* Company
* Overview
* Board of Directors
* Management
* Partnerships
* Careers
* Vaccines
* Moditope
* Immunobody
* Vaccine Publications
* Antibodies
* GlyMab
* AvidiMab
* Antibody Publications
* Investors
* Company Profile
* Advisors
* Corporate Governance
* Documents & Presentations
* Share Information
* Financial Information
* Regulatory News
* News
* Latest News
* Contact Us
* Privacy
NEWS UPDATES
Sign up for news updates to stay up to date with Scancell
Email
Privacy & legal notes ©Copyright Scancell 2023